Although the anticancer activities of naringenin have been widely reported, recent experimental evidence indicates that naringenin inhibits TSGH-8301 bladder cancer cell migration via deactivation of AKT signaling and MMP-2 downregulation (50). This evidence concerns the gene AKT1 and urinary bladder carcinoma.